Skip to content

Psilocybin: all studies

Page 222 of 439: studies 2,211 to 2,220 of 4,389, newest first. Back to the psilocybin overview

Research

Use of Prescribed and Non-Prescribed Treatments for Cluster Headache in a Swedish Cohort

Brain Sciences March 31, 2024 Gabriella Smedfors, Felicia Jennysdotter Olofsgård, Anna Steinberg et al. 4 citations

Background: Cluster headache (CH) is a debilitating condition, but current therapies leave CH patients in pain. The extent of this problem in Sweden is unknown. Methods: An anonymized questionnaire was sent to 479 Swedish CH patients to investigate patterns and perceived effects of treatments. Results: Three hundred fourteen answers were analyzed. The population was representative regarding age...

DOI: 10.3390/brainsci14040348 (opens in new tab) Abortive Illicit substances Preventive Medication side effects +4

Psychedelic Drugs: A Mind-expanding Hallucinogens

Indian Journal of Behavioural Sciences March 22, 2024 Shreyasee Das, Rahul Shil

Psychedelics are mainly from the class of psychoactive substances whose action is to produce changes in the perception, mood, cognitive behavior, and processes of a person. This psychedelic drug creates an alteration in a person’s thinking, sense of time, and emotions. Hallucinations can be a main cause for people who take psychedelics. Mainly, these psychedelic drugs have been used since...

A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder

Brain Sciences March 3, 2024 Mario Renato Velit-Salazar, Eloise Cherian, Paulo R Shiroma 13 citations

Objective: This study aims to provide an overview of pharmacological trials that examine the neurocognitive effects of psychedelics among healthy individuals and patients with post-traumatic stress disorder (PTSD) or major depressive disorder (MDD). Methods: The Preferred Reporting Items for Systematic Reviews (PRISMA) was used as a guide to structure and report the findings for this review. A...

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain

Journal of Pain Research March 1, 2024 Christopher L. Robinson, Alexandra Fonseca, Efemena Diejomaoh et al. 32 citations

Psychedelics may have potential in alleviating pain symptoms secondary to a multitude of chronic pain conditions. However, further randomized, double-blind, placebo-controlled trials are needed to further explore and evaluate the role of psychedelics in chronic, non-cancer pain.

DOI: 10.2147/jpr.s439348 (opens in new tab) Psilocybin Chronic pain Medline Hallucinogen

The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item.

Psychedelic Medicine March 1, 2024 Justin C Strickland, Albert Garcia‐romeu, Matthew W Johnson 20 citations

The Mystical Experience Questionnaire (MEQ-30) and Challenging Effects Questionnaire (CEQ) are two of the most widely used, validated instruments to probe subjective effects of psychedelic drugs. However, these assessments are lengthy and can be a burden to study participants or patients if administered during acute psychedelic effects, after resolution of psychedelic effects when participants...

Development of a digital intervention for psychedelic preparation (DIPP).

Scientific Reports February 19, 2024 Rosalind McAlpine, Matthew D. Sacchet, Otto Simonsson et al. 13 citations

Psychedelic substances induce profound alterations in consciousness. Careful preparation is therefore essential to limit adverse reactions, enhance therapeutic benefits, and maintain user safety. This paper describes the development of a self-directed, digital intervention for psychedelic preparation. Drawing on elements from the UK Medical Research Council (MRC) framework for developing...

Psychedelic Microdosing among Young Adults from Southern California

Journal of Psychoactive Drugs February 10, 2024 Alyssa F. Harlow, Peter S. Hendricks, Adam M. Leventhal et al. 6 citations

Despite common depictions in the media, there is little scientific evidence on microdosing psychedelic drugs. We assessed awareness, prevalence, and dosing practices of microdosing psychedelic drugs among young adults 18-22 years old from Southern California (2018-2019). We examined whether sociodemographic factors, personality traits, mental health, or other substance use behaviors were...

Psychedelics and sexual functioning: a mixed-methods study

Scientific Reports February 7, 2024 Tommaso Barba, Hannes Kettner, Caterina Radu et al. 24 citations

Abstract Do psychedelics affect sexual functioning postacutely? Anecdotal and qualitative evidence suggests they do, but this has never been formally tested. While sexual functioning and satisfaction are generally regarded as an important aspect of human wellbeing, sexual dysfunction is a common symptom of mental health disorders. It is also a common side effect of selective serotonin reuptake...

DOI: 10.1038/s41598-023-49817-4 (opens in new tab) Full text (opens in new tab) Psilocybin Escitalopram Clinical psychology Sexual dysfunction +2

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology February 2, 2024 Joachim Neumann, Stefan Dhein, Uwe Kirchhefer et al. 12 citations

Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT 2A -serotonin receptors in the brain. However, a close study reveals that they also act on the heart, possibly increasing the force of contraction and beating rate and may lead to arrhythmias. Here, we will review...

Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach

Frontiers in Psychiatry February 1, 2024 Phil Wolfson, Gita Vaid 17 citations

Psychiatry is in a growth phase in which several psychedelic medicines have entered its arena with great promise. Of these, presently, ketamine is the only medicine that may be legally prescribed. We hypothesize that at subanesthetic doses, ketamine produces a unique spectrum of altered states, ranging from psychoactive to deep ego-dissolving experiences, that are intrinsic to ketamine’s...